



In Hypertensive Emergencies

You Have No Time to Waste

Update to Ready-to-Use CARDENE I.V.

- Provides smooth, predictable blood pressure control¹
- Enables practical point-of-use storage²
- Offers instant access for rapid intervention^{2,3}
- Eliminates medication admixture errors

Ready-to-Use CARDENE I.V. is indicated for short-term management of hypertension when oral therapy is not feasible or desirable.¹

READY-TO-USE BAG

CARDENE® I.V.
(nicardipine hydrochloride)
PREMIXED INJECTION



Ready-to-Use CARDENE® I.V. SPECIFICATIONS		
	40 mg in 200 mL (0.2 mg/mL)	20 mg in 200 mL (0.1 mg/mL)
Drug Description	CARDENE I.V. Premixed Injection in either 0.83% Sodium Chloride or 5.0% Dextrose Galaxy® Ready-to-Use Bag with 40 mg in 200 mL (0.2 mg/mL)	CARDENE I.V. Premixed Injection in either 0.86% Sodium Chloride or 4.8% Dextrose Galaxy® Ready-to-Use Bag with 20 mg in 200 mL (0.1 mg/mL)
Stability/Storage	Manufacturer stability is 12 months. Protect from light, store in carton at controlled room temperature until ready to use. Refer to USP Controlled Room Temperature	Manufacturer stability is 12 months. Protect from light, store in carton at controlled room temperature until ready to use. Refer to USP Controlled Room Temperature
Dimensions	Box size: 9" H x 4.75" W x .875" D (contains 1 Ready-to-Use Bag)	Box size: 9" H x 4.75" W x .875" D (contains 1 Ready-to-Use Bag)
NDC Numbers	<ul style="list-style-type: none"> • Sodium Chloride: NDC # 24477-323-02 (1 pack of 10 boxes/bags) • Dextrose: NDC # 24477-324-02 (1 pack of 10 boxes/bags) 	<ul style="list-style-type: none"> • Sodium Chloride: NDC # 24477-311-02 (1 pack of 10 boxes/bags) • Dextrose: NDC # 24477-312-02 (1 pack of 10 boxes/bags)

Ready-to-Use CARDENE® I.V. 40 mg in 200 mL (0.2 mg/mL)

ORDERING INFORMATION

Wholesaler	Product	Wholesaler Order Numbers
AmerisourceBergen	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	006-577
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	008-946
Cardinal Health	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	4225173
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	4217923
H. D. Smith	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	221-0243
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	221-0250
McKesson	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	2538692
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	1437169
Morris & Dickson	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	977876
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	946780

Please contact your GPO administrator for Ready-to-Use CARDENE I.V. contract pricing.

Supports compliance with The Joint Commission (TJC) standards and American Society of Health-System Pharmacists (ASHP) guidelines for dispensing and storing medications: When possible, medications shall be available in a ready-to-administer form.^{4,5}

Ready-to-Use CARDENE® I.V. 20 mg in 200 mL (0.1 mg/mL)

ORDERING INFORMATION

Wholesaler	Product	Wholesaler Order Numbers
AmerisourceBergen	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	777-060
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	830-455
Cardinal Health	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	4236352
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	4239638
H. D. Smith	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	218-0867
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	218-0875
McKesson	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	1438753
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	1225234
Morris & Dickson	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	989632
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	991596

Please contact your GPO administrator for Ready-to-Use CARDENE I.V. contract pricing.

Supports compliance with TJC standards and ASHP guidelines for dispensing and storing medications: When possible, medications shall be available in a ready-to-administer form.^{4,5}

Important Safety Information

Close monitoring of the blood pressure is required during therapy. CARDENE I.V. is contraindicated in patients with known hypersensitivity to the drug and in patients with advanced aortic stenosis. Reduction of diastolic pressure and reduced afterload may worsen rather than improve myocardial oxygen balance. Caution is advised when administering CARDENE I.V. to patients with impaired renal or hepatic function, in combination with a beta-blocker in patients with congestive heart failure, or portal hypertension. Observe caution in patients with significant left ventricular dysfunction due to possible inotropic effect. CARDENE I.V. gives no protection against the dangers of abrupt beta-blocker withdrawal; beta-blocker dosage should be gradually reduced. Levels of cyclosporine should be closely monitored during therapy. The most common side effects of CARDENE I.V. are headache (14.6%), hypotension (5.6%), nausea/vomiting (4.9%), and tachycardia (3.5%). Less frequent adverse effects, in each case occurring at 1.4%, include ECG abnormalities, postural hypotension, ventricular extrasystoles, injection-site reaction, dizziness, sweating and polyuria.

Please [click here](#) for full prescribing information.

For more information, visit www.cardeneiv.com or e-mail us at cardeneiv@ekrtx.com.

For any additional questions, contact EKR Medical Information at 1-877-207-5802.

References: 1. CARDENE I.V. prescribing information, 2008. EKR Therapeutics, Bedminster, NJ. 2. Ruble J. Impact safety, efficiency, and the bottom line with premixed IV products. *Pharma Purchasing Prod.* February 2008:34-38, vi. 3. Fanikos J, Erickson A, Munz KE, et al. Observations on the use of ready-to-use and point-of-care activated parenteral products in automated dispensing cabinets in U.S. hospitals. *Am J Health-Syst Pharm.* 2007;64(19):2037-2043. 4. Rich DS. New JCAHO medication management standards for 2004. *Am J Health-Syst Pharm.* 2004;61(13):1349-1358. 5. American Society of Health-System Pharmacists. ASHP guidelines: minimum standard for pharmacies in hospitals. *Am J Health-Syst Pharm.* 1995;52(23):2711-2717.

CARDENE® is a registered trademark of EKR Therapeutics, Inc.
Galaxy® is a registered trademark of Baxter International.

